ESMO 2025 | DAREON-8研究首次揭曉，Obrixtamig探索ES-SCLC一線治療新路徑

*僅供醫學專業人士閱讀參考

*以下內容僅供醫療衛生專業人士瀏覽。

調研問題

專家簡介

艾星浩 教授

上海市胸科醫院 腫瘤內科

• 醫學博士，上海市胸科醫院肺部腫瘤臨床醫學中心副主任醫師，碩士生導師

• 中國醫藥教育協會腫瘤免疫治療專業委員會委員
  

• 中國抗癌協會科普委員會委員
  

• 中國抗癌協會免疫治療專業委員會委員
  

• 中國肺癌防治聯盟肺癌免疫治療委員會委員
  

• 吳階平醫學基金會腫瘤多學科診療專業委員會副秘書長
  

• 上海市女醫師協會肺癌專業委員會副主任委員
  

• 上海市抗癌協會腫瘤免疫治療專業委員會秘書長
  

• 上海市康復醫學醫療器械專業委員會委員

• JCO

  中文編委

• 2021年獲中華醫學科學技術獎二等獎
  

• 2023年獲上海醫學科技獎一等獎

參考文獻：

[1]中國臨床腫瘤學會小細胞肺癌專家委員會, 中國醫師協會腫瘤多學科診療專業委員會. 小細胞肺癌免疫治療專家共識（2025版）. 中華腫瘤雜志. 2025. 47(01): 65-75.

[2]Ogieuhi IJ, Ajekiigbe VO, Oladipo TC, et al. Bispecific T-cell engagers (BiTE): a review of tarlatamab in small cell lung cancer. Clin Transl Oncol. 2025 .

[3]Lally BE, Urbanic JJ, Blackstock AW, Miller AA, Perry MC. Small cell lung cancer: have we made any progress over the last 25 years. Oncologist. 2007. 12(9): 1096-104.

[4]Solange Peters, et al. DAREON?-8: A phase I trial of first-line obrixtamig plus chemotherapy and atezolizumab in extensive-stage small cell lung carcinoma (ES-SCLC). 2025 ESMO. 2759MO .

[5]鄭榮壽, 陳茹, 韓冰峰等. 2022年中國惡性腫瘤流行情況分析. 中華腫瘤雜志. 2024. 46(03): 221-231.

[6]Wermke M, Gambardella V, Kuboki Y, et al. Phase I Dose-Escalation Results for the Delta-Like Ligand 3/CD3 IgG-Like T-Cell Engager Obrixtamig (BI 764532) in Patients With Delta-Like Ligand 3+ Small Cell Lung Cancer or Neuroendocrine Carcinomas. J Clin Oncol. 2025. 43(27): 3021-3031.

[7]Xie J, Chen M, Han H, et al. Clinical impact of first-line PD-1 or PD-L1 inhibitors combined with chemotherapy in extensive-stage small cell lung cancer patients: A real-world multicenter propensity score-matched study. Thorac Cancer. 2023. 14(15): 1327-1338.

[8]Horn L, Mansfield AS, Szcz?sna A, et al. First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer. N Engl J Med. 2018. 379(23): 2220-2229.

[9]Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021. 22(1): 51-65.

[10]Wang J, Zhou C, Yao W, et al. Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2022. 23(6): 739-747.

[11]Cheng Y, Fan Y, Zhao Y, et al. Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial. J Thorac Oncol. 2024. 19(7): 1073-1085.

[12]Cheng Y, Zhang W, Wu L, et al. Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial. JAMA Oncol. 2025. 11(1): 16-25.

[13]Martin Wermke, Jürgen Alt, Farastuk Bozorgmehr, et al. DAREON-9, a phase Ib study of obrixtamig plus topotecan in patients (pts) with advanced small cell lung cancer (SCLC): Interim analysis results. 2025 ASCO Abstract 8094 .

[14]Martin Wermke, Juergen Alt, Farastuk Bozorgmehr, et al. DAREON?-9: A phase Ib open-label dose escalation and dose confirmation study of obrixtamig (BI 764532) plus topotecan in patients (pts) with advanced small-cell lung cancer (SCLC): Updated results. 2025 ESMO. 2774P .

[15]Marianne E. Pavel, Chris Verslype, Pedro Rocha, et al. Obrixtamig (BI 764532) in patients (pts) with relapsed/refractory delta-like ligand 3 (DLL3)-high expressing extrapulmonary neuroendocrine carcinoma (epNEC): Trial in progress of the dose expansion part of the phase II DAREON?-5 trial. 2025 ESMO. 1731TiP .

[16]Aman Chauhan, Saori Mishima, Ana Custodio, et al. DAREON?-7: Phase I open-label dose-escalation/-expansion study of first-line obrixtamig (BI 764532) plus platinum-doublet chemotherapy in patients with DLL3-positive neuroendocrine carcinomas. 2025 NANETS. -8 .

審批號：SC-CN-18189, 有效期至：11/3/2026

*此文僅用于向醫療衛生專業人士提供科學信息，不代表平臺立場。